Filing Details
- Accession Number:
- 0001731122-21-000308
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-26 21:31:59
- Reporting Period:
- 2021-02-24
- Accepted Time:
- 2021-02-26 21:31:59
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1314052 | Anavex Life Sciences Corp. | AVXL | Services-Commercial Physical & Biological Research (8731) | 208365999 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1608022 | Elliot Favus | 51 W 52Nd Street, 7Th Floor New York NY 10019 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-02-24 | 45,500 | $2.58 | 45,000 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2021-02-24 | 100,000 | $3.28 | 145,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-02-24 | 145,500 | $12.66 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2021-02-24 | 45,500 | $0.00 | 45,500 | $2.58 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2021-02-24 | 100,000 | $0.00 | 100,000 | $3.28 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2028-10-01 | No | 4 | M | Direct | |
| 0 | 2016-09-22 | 2026-09-22 | No | 4 | M | Direct |
Footnotes
- The options vested upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials.
Billionaire Hedge Funds
